ArticleDiscover oncology2025
Predicting survival and immune status of breast cancer patients based on prognostic features related to PANoptosis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Immunotherapy impact of macrophage glycosylation on cholangiocarcinoma and its prognostic and immune microenvironment significance.Human vaccines & immunotherapeutics · 2026Article
- Development of a diagnostic model using the circulating long noncoding RNAs LINC00857 and KLHDC7B-DT in lung adenocarcinoma.Journal of thoracic disease · 2026Article
- Exosome crown proteins are promising markers for liquid biopsy of breast cancer.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer (BRCA) is a prevalent female malignancy. PANoptosis, integrating diverse cell death traits, is pivotal in BRCA, thus necessitating deeper study.
methodsData from Gene Expression Omnibus (GEO, GSE180286 and GSE20685) and The Cancer Genome Atlas (TCGA) were analyzed. Weighted gene co-expression network analysis (WGCNA) identified PANoptosis-related genes in BRCA patients from TCGA. Further refinement of these module genes was conducted through univariate Cox regression, LASSO regression (glmnet package), and stepwise multivariate regression analysis to derive the final biomarkers. Based on these biomarkers, a risk model was established, and in-vitro experiments (wound healing assay, Transwell assay, and qRT-PCR) were carried out to validate the accuracy of these biomarkers. The MCPcounter package and the oncoPredict package were used to assess immune cell infiltration and sensitivity to drugs in BRCA patients, respectively.
resultsThis study identified 8 biomarkers (ACY3, CD83, CXCL13, KLHDC7B, NR1H3, SMCO4, TRPM2, and UPP1) and established a risk model. In-vitro experiments revealed significant differences in biomarker expression between BRCA cells and the control group, with TRPM2 knockdown inhibiting BRCA cell migration and invasion. Enrichment analysis showed metabolic pathways were activated in high-risk group. Additionally, immune analysis showed lower immune cell enrichment and significant enrichment of fibroblasts in the high-risk group. Drug sensitivity analysis linked 13 drugs to RiskScore. Finally, single-cell analysis identified six cell types (including cancer stem cells, fibroblasts, T-cells, macrophages, B/Plasma cells, and endothelial cells) for BRCA and found that macrophages had higher PANoptosis activity.
conclusionThe current research introduces a novel model for BRCA prognosis analysis but also provides a fresh perspective on BRCA treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.